Yuyun Lusiyani
A prominent Colorado manufacturer of marijuana vapes, StayCon, last week initiated a recall of 49 products due to contamination with methylene chloride, a chemical widely recognized by the Environmental Protection Agency (EPA) as a carcinogen. This significant recall casts a stark spotlight on a protracted delay in Colorado’s implementation of expanded state-level testing procedures, which, had they been in effect, would have detected this and other hazardous solvents. The incident underscores deeper systemic issues within the state’s pioneering regulated marijuana market, raising serious questions about consumer safety, regulatory oversight, and the efficacy of public health protections.
The Recall Unfolds: StayCon’s Action and Delayed Notification
StayCon, operating under the brand name Craft from Pueblo County, voluntarily flagged 49 of its vape products after a third-party laboratory identified the toxic solvent. Among the recalled items are popular brands such as Maui Wowie and Grape Gorilla, some of which had been available on dispensary shelves for over 18 months, exposing consumers to potentially harmful substances for an extended period. The manufacturer’s recall notice specified that a "botanically-derived" flavoring compound used in its marijuana vapes was the source of the methylene chloride contamination. Despite StayCon’s voluntary action, the state’s official response has been notably slow and opaque.
The discovery of the contamination traces back to August when Denver-based Bona Fides Laboratory detected methylene chloride during routine testing for other contaminants like pesticides and mold. David Mathis, owner of Bona Fides, stated that he immediately notified both StayCon and the state’s Marijuana Enforcement Division (MED) approximately six weeks prior to StayCon’s public recall notice. This timeline indicates a significant lag between the state agency receiving critical information about a public health risk and its failure to issue a timely alert to consumers. When questioned about the delay in making the recall public, Kyle Boyd, a spokesperson for the Colorado Marijuana Enforcement Division, offered a terse "does not comment on investigations," a response that has drawn criticism for its lack of transparency given the potential public health implications. StayCon itself has not responded to inquiries from The Denver Gazette and ProPublica regarding the recall.
Methylene Chloride: A Known Carcinogen and Regulatory Quagmire
Methylene chloride, also known as dichloromethane (DCM), is a colorless liquid with a sweet, penetrating odor that has various industrial uses, including as a paint stripper, degreaser, and aerosol propellant. Its presence in marijuana vape products is particularly alarming due to its severe health risks. The EPA has actively sought to ban methylene chloride for most uses, culminating in a 2024 ban that was, however, recently struck down by the U.S. Court of Appeals for the 5th Circuit, sending the matter back to the agency for further review. Despite this judicial setback for the EPA, the scientific consensus on its toxicity remains clear: methylene chloride is classified as a human carcinogen, and exposure can lead to central nervous system depression, liver damage, kidney damage, cardiac arrest, and even death, particularly with high or prolonged exposure.
In the context of the marijuana industry, methylene chloride is sometimes illicitly used to cheaply synthesize hemp-derived CBD into delta-9 THC, the primary psychoactive compound in marijuana. This chemically converted hemp is then often falsely labeled and sold as legitimate marijuana-based products, bypassing stricter cultivation and testing regulations. Colorado state law explicitly bans this chemical conversion process and prohibits marijuana manufacturers from using methylene chloride in their products, highlighting the direct violation represented by StayCon’s contaminated vapes. The discovery of this chemical in products on dispensary shelves underscores the critical failure of the existing regulatory framework to prevent such hazardous substances from reaching consumers.
Colorado’s Protracted Regulatory Delays and Unimplemented Protections
The current recall is not an isolated incident but rather a symptom of broader, long-standing regulatory shortcomings in Colorado. The state’s plan to implement expanded testing for methylene chloride and 30 other solvents was designed to bring Colorado’s standards in line with those already mandated in 24 of the 43 states that operate regulated marijuana markets. This crucial upgrade was initially slated for implementation in July – nearly three months before StayCon informed dispensaries of its recall. However, the MED spokesperson stated that the state public health department, responsible for reviewing labs and recommending their certification, requested more time. Implementation is now projected to begin at the end of this month, a delay that has potentially left consumers exposed to dangerous contaminants for months longer than necessary.
David Mathis of Bona Fides Laboratory sharply criticized these delays, emphasizing that his company was fully prepared to conduct the expanded screenings since the beginning of July. His pointed question, "How many samples were not tested but have contaminants in them and were passed to the public?" encapsulates the profound concern facing consumers and legitimate industry stakeholders. Previous investigative reports by The Denver Gazette and ProPublica have consistently highlighted Colorado’s regulatory loopholes, detailing how contaminated marijuana products, posing significant health risks, have been sold to consumers for months, sometimes even years. These reports have also documented regulators’ slow response in issuing public warnings, even after receiving reports of consumer harm. Earlier this year, the publications specifically reported on the dangers of methylene chloride as part of an investigation into Colorado’s failure to adopt many regulations utilized by other states to keep intoxicating hemp products off marijuana shelves.
A History of Regulatory Weakness: The Hemp-THC Conversion Challenge
Colorado holds a unique position as one of the first states to legalize recreational marijuana sales in January 2014. However, its pioneering status has also exposed it to unforeseen challenges, particularly concerning the intersection of the marijuana and hemp industries.
The 2018 Farm Bill, signed by President Donald Trump in December 2018, legalized hemp, aiming to support farmers and provide access to non-intoxicating CBD products for therapeutic uses. However, this legislation inadvertently created a regulatory vacuum, as hemp companies quickly discovered methods to chemically convert CBD into the intoxicating compound THC.
Colorado was among the first states to recognize the potential dangers and market disruptions posed by these chemically converted hemp products. In May 2021, the state issued regulatory advisories and subsequently passed legislation to ban such products, aiming to protect consumers and the integrity of the regulated marijuana market. Despite these efforts, the problem has persisted.
Investigative reports earlier this year, including those from The Denver Gazette and ProPublica, underscored the dangers of methylene chloride in this context, specifically its use in creating cheap, unregulated intoxicating hemp products that often find their way onto marijuana dispensary shelves, sometimes mislabeled.
In April 2026, state regulators announced a plan to "crack down on companies" illegally selling these cheaper and potentially hazardous hemp products, citing "serious risks to public safety" and potential tax avoidance. This acknowledgement was further compounded in May 2026, when a top MED official admitted in a meeting with industry representatives that the amount of chemically converted hemp being sold as marijuana was "greater than the agency has publicly disclosed." This history paints a picture of regulators constantly playing catch-up, with public safety often taking a back seat to market dynamics and bureaucratic inertia.
The Persistent Sampling Loophole: Industry Influence on Safety Protocols
Even as Colorado belatedly moves to implement expanded testing protocols, a critical and longstanding regulatory loophole remains unaddressed, further compromising consumer safety: marijuana manufacturers are still permitted to choose both the laboratories that test their products and the specific samples submitted for testing. This practice introduces an inherent conflict of interest, creating opportunities for "lab shopping" – where manufacturers select labs known for more lenient results – or for submitting only "clean" samples while potentially contaminated batches reach consumers.
In January 2026, state regulators had discussed a proposal to fundamentally overhaul these sampling rules, requiring independent lab personnel or contractors to collect samples directly from production facilities. This reform would have significantly enhanced the integrity of the testing process by eliminating the manufacturer’s ability to cherry-pick samples. However, these plans were abandoned after top manufacturers reportedly argued that such a system would be too expensive, highlighting the pervasive influence of industry interests on regulatory decisions.
This decision contrasts sharply with best practices in other highly regulated industries, such as pharmaceuticals and food safety, where independent sampling is often a cornerstone of consumer protection. The continued allowance of manufacturer-selected samples undermines the very purpose of testing, creating a chink in the armor of Colorado’s public health safeguards.
Broader Implications for Consumer Trust and Market Integrity
The StayCon recall and the surrounding regulatory failures carry profound implications for Colorado’s marijuana market. Foremost among these is the erosion of public trust. Consumers who rely on a regulated market for safe products may question the state’s ability to protect them when known carcinogens can persist in products on shelves for over a year and a half, and when regulators delay public notification.
From a public health perspective, the continued presence of hazardous chemicals like methylene chloride poses an ongoing threat, with potential long-term health consequences for users. For the industry, this incident risks damaging the reputation of Colorado’s pioneering legal cannabis market, potentially affecting sales and investment. Legitimate businesses that adhere to stringent safety protocols are unfairly disadvantaged by competitors who exploit loopholes or cut corners, creating an uneven playing field.
Furthermore, the "no comment" stance from the MED and the delayed public alerts raise questions about transparency and accountability within the regulatory body itself. Effective regulation demands not only robust rules but also clear communication and swift action when public health is at risk.
Looking Ahead: Promises of Reform Amidst Lingering Concerns
While the MED has promised that the expanded testing protocols will finally begin implementation at the end of this month, the overarching concerns about regulatory effectiveness persist. The sampling loophole, a critical vulnerability in the system, remains unaddressed, leaving the door open for future instances of contamination and fraud.
The ongoing scrutiny from investigative journalism by The Denver Gazette and ProPublica remains vital in holding regulators accountable and pushing for necessary reforms. The fundamental question posed by lab owner David Mathis – "How many samples were not tested but have contaminants in them and were passed to the public?" – continues to resonate, underscoring the urgent need for proactive, transparent, and comprehensive regulation rather than reactive measures taken only after a public health crisis emerges.
As Colorado navigates these challenges, the integrity and safety of its marijuana market hang in the balance. The StayCon recall serves as a potent reminder that without robust, independently verifiable testing and a commitment to prioritizing public health over industry convenience, the promise of a safe and well-regulated cannabis industry remains unfulfilled.
Jia Lissa
Joko Widodo
Eva Lovia
Pevita Pearce